BEIGF:OTCMKTS
BeOne Medicines
21,95 USD
0,00%
(0,00) 1D
9. lip, 12:49:46 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za BEIGF...
Trž. kap.
42,40 mlr.
Prosj. kol.
0,00
Količina
0,00
52-tjed. najviša
24,92 USD
52-tjed. najniža
21,95 USD
Beta
0,84
Dionice u optjecaju
1,43 mlr.
Broj djelatnika
12 tis.
Trž. kap.
42,40 mlr.
Prosj. kol.
0,00
Količina
0,00
52-tjed. najviša
24,92 USD
52-tjed. najniža
21,95 USD
Beta
0,84
Dionice u optjecaju
1,43 mlr.
Broj djelatnika
12 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
hr.bloombergadria.com
·
prije 2 dana
Trump slavi rekorde na Wall Streetu, ali iza burzovne euforije krije se opasna istina
Simply Wall Street
·
prije 13 minuta
Does Advanced Micro Devices (AMD) Face New AI Demand Risk After A Customer Reset?
Barchart.com
·
prije 1 sat
The S&P 500 Is Near Record Highs. So Why Does Your Portfolio Feel Like a Bear Market?
Bloomberg.com
·
prije 1 sat
Oil Rises on Mideast Attacks, Dollar Edges Higher: Markets Wrap
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
BeOne Medicines – informacije
Glavni izvršni direktorJohn Vincent Oyler | John Vincent Oyler
Zaposlenici12 tis.
Osnovano28. lis 2010.
Sjedište-
Sektor-
Web-lokacijabeonemedicines.com